Randomized, double-blind, placebo-controlled, phase III study to assess the efficacy and safety of weekly MORAb-003 in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse (MORAb-003-004; NCT00849667) |
Platinum-sensitive EOC (1100 patients) in first relapse |
No significant differences in PFS among the treatment arms were observed. The primary end point of PFS was not met. |
[116,118] |
Phase III randomized clinical trial of weekly paclitaxel with or without farletuzumab (MORAb-003-003; NCT00738699) |
Platinum-resistant ovarian cancer (417 patients) |
Study was terminated due to failure to meet pre-specified criteria. |
[117] |
Vintafolide (EC145) |
Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil® (PROCEED) (EC-FV-06; NCT01170650) |
FRα-positive platinum-resistant ovarian cancer (640 patients) |
Trial was terminated owing to failure to meet pre-specified PFS criteria. |
[125] |
Mirvetuximab soravtansine |
Phase III RCT (FORWARD I) evaluating chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) vs. mirvetuximab soravtansine (IMGN853-0403; NCT02631876) |
FRα-positive platinum-resistant ovarian cancer (366 patients) |
Mirvetuximab soravtansine did not result in a significant improvement in PFS compared with chemotherapy. |
[121] |